Home
Cancer
October 16, 2014
Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment.
Successful treatment depends in part on accurately identifying the type of tumour, but this can be difficult. As a result, many women with cancer are not sent to the right specialist surgeon, or those with a benign cyst may have a more serious operation than they need.
In a study published today in the British Medical Journal, an international team led by Imperial College London and KU Leuven, Belgium describe a new test, called ADNEX, which can discriminate between benign and malignant tumours, and identify different types of malignant tumour, with a high level of accuracy.
The test is based on the patient’s clinical information, a simple tumour marker blood test and features that can be identified on an ultrasound scan. As well as identifying the type of tumour, the test expresses the confidence of the diagnosis as a percentage.
Doctors can use the test in a clinical database or by entering the patient’s details into a smartphone app, which was demonstrated to gynaecologists at the International Society for Ultrasound in Obstetrics and Gynecology World Congress in Barcelona last month.. The authors of the study say doctors could start using ADNEX straight away.
Professor Tom Bourne, from the Department of Surgery and Cancer at Imperial College London, said: “It’s very important to get the preoperative diagnosis right. If it isn’t right, the patient might have a more extensive operation than they need, for example having an ovary removed unnecessarily.
“If a tumour is benign, a woman might not need any treatment at all. If it is malignant, you need to know what type of tumour it is to choose the best treatment and that treatment needs to be carried out by specialist gynaecological cancer surgeon”
“At the moment, the way we assess women with ovarian cysts for the presence of cancer and select treatment lacks accuracy. This new approach to classifying ovarian tumours can help doctors make the right management decisions, which will improve the outcome for women with cancer. It will also reduce the likelihood of women with all types of cysts having excessive or unnecessary treatment that may impact on their fertility”
The researchers developed the test using data from 3,506 patients from 10 European countries from 1999 to 2007, looking at which information available before the operation could be used to predict the diagnosis. They then tested the model on a further 2,403 patients between 2009 and 2012.
Studies have shown that ovarian cancer patients have a better chance of survival if they are referred to a specialised gynaecological cancer unit, but this only happens for a minority of women in Europe and the US at present.
Apart from the tumour type, the choice of treatment sometimes has to take into account implications for the woman’s fertility.
Existing prediction models discriminate between benign and malignant tumours but lack accuracy and don’t sub-classify malignant tumours. The ADNEX model can discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary metastatic tumours.
Explore further: New technique could improve the outcome of breast cancer surgery
More information: British Medical Journal www.bmj.com/cgi/doi/10.1136/bmj.g5920
Medical Xpress on facebook
Related Stories
New research shows ‘DNA tags’ could guide treatment for advanced ovarian cancer
Oct 15, 2013
A Cancer Research UK study has identified chemical ‘tags’ on DNA in patients’ tumours that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive, according to …
New technique could improve the outcome of breast cancer surgery
Sep 30, 2014
A new technique will help surgeons to detect where the margins of cancerous breast tumours are during surgery, reducing the need for secondary operations in breast cancer patients.
Study reveals benign brain tumours can cause more emotional harm than malignant tumours
Oct 22, 2012
(Medical Xpress)—In a paper published in the Journal of Neuro-oncology, researchers have found that that patients with benign brain tumours experience greater distress than those with malignant tumours before …
Benefit of PET and PET/CT in ovarian cancer is not proven
Aug 08, 2012
Due to the lack of studies, there is currently no proof that patients with ovarian cancer can benefit from positron emission tomography (PET) alone or in combination with computed tomography (CT). As regards diagnostic accuracy, …
New blood test could offer more tailored treatment of ovarian cancer
Sep 05, 2014
(Medical Xpress)—A new blood test allowing doctors to predict which ovarian cancer patients will respond to particular types of treatment is a step closer following a new study by Manchester scientists.
Recommended for you
New imaging technique identifies receptors for targeted cancer therapy
8 hours ago
Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in “Quantitative in vivo …
Cutting-edge computer software helps pinpoint aggressiveness of breast cancer tumors
8 hours ago
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast …
Conventional therapies are less efficient in cancer patients carrying ‘BRCA’ mutations
13 hours ago
Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy – and they also have a lower survival rate than those …
Chlamydia knocks out the body’s own cancer defence
13 hours ago
Infections due to the sexually transmitted bacterium Chlamydia trachomatis often remain unnoticed. The pathogen is not only a common cause of female infertility; it is also suspected of increasing the ri …
Researchers develop technology to improve lung cancer detection and treatment
13 hours ago
Researchers from Loyola University Chicago Stritch School of Medicine have developed a technology that improves the detection of tumors during radiation therapy for early-stage lung cancer.
Studies on Curaxin CBL0137 in preclinical models of pancreatic cancer
14 hours ago
Cleveland BioLabs, Inc. and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the …
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Privacy Policy
Terms of use
Disclaimer
© Medical Xpress 2011-2014, Science X network
Home
Cancer
October 16, 2014
Researchers have devised a new test to help doctors diagnose ovarian tumours and choose the most appropriate treatment.
Successful treatment depends in part on accurately identifying the type of tumour, but this can be difficult. As a result, many women with cancer are not sent to the right specialist surgeon, or those with a benign cyst may have a more serious operation than they need.
In a study published today in the British Medical Journal, an international team led by Imperial College London and KU Leuven, Belgium describe a new test, called ADNEX, which can discriminate between benign and malignant tumours, and identify different types of malignant tumour, with a high level of accuracy.
The test is based on the patient’s clinical information, a simple tumour marker blood test and features that can be identified on an ultrasound scan. As well as identifying the type of tumour, the test expresses the confidence of the diagnosis as a percentage.
Doctors can use the test in a clinical database or by entering the patient’s details into a smartphone app, which was demonstrated to gynaecologists at the International Society for Ultrasound in Obstetrics and Gynecology World Congress in Barcelona last month.. The authors of the study say doctors could start using ADNEX straight away.
Professor Tom Bourne, from the Department of Surgery and Cancer at Imperial College London, said: “It’s very important to get the preoperative diagnosis right. If it isn’t right, the patient might have a more extensive operation than they need, for example having an ovary removed unnecessarily.
“If a tumour is benign, a woman might not need any treatment at all. If it is malignant, you need to know what type of tumour it is to choose the best treatment and that treatment needs to be carried out by specialist gynaecological cancer surgeon”
“At the moment, the way we assess women with ovarian cysts for the presence of cancer and select treatment lacks accuracy. This new approach to classifying ovarian tumours can help doctors make the right management decisions, which will improve the outcome for women with cancer. It will also reduce the likelihood of women with all types of cysts having excessive or unnecessary treatment that may impact on their fertility”
The researchers developed the test using data from 3,506 patients from 10 European countries from 1999 to 2007, looking at which information available before the operation could be used to predict the diagnosis. They then tested the model on a further 2,403 patients between 2009 and 2012.
Studies have shown that ovarian cancer patients have a better chance of survival if they are referred to a specialised gynaecological cancer unit, but this only happens for a minority of women in Europe and the US at present.
Apart from the tumour type, the choice of treatment sometimes has to take into account implications for the woman’s fertility.
Existing prediction models discriminate between benign and malignant tumours but lack accuracy and don’t sub-classify malignant tumours. The ADNEX model can discriminate between benign, borderline, stage I invasive, stage II-IV invasive, and secondary metastatic tumours.
Explore further: New technique could improve the outcome of breast cancer surgery
More information: British Medical Journal www.bmj.com/cgi/doi/10.1136/bmj.g5920
Medical Xpress on facebook
Related Stories
New research shows ‘DNA tags’ could guide treatment for advanced ovarian cancer
Oct 15, 2013
A Cancer Research UK study has identified chemical ‘tags’ on DNA in patients’ tumours that could help doctors decide the type of chemotherapy women with advanced ovarian cancer should receive, according to …
New technique could improve the outcome of breast cancer surgery
Sep 30, 2014
A new technique will help surgeons to detect where the margins of cancerous breast tumours are during surgery, reducing the need for secondary operations in breast cancer patients.
Study reveals benign brain tumours can cause more emotional harm than malignant tumours
Oct 22, 2012
(Medical Xpress)—In a paper published in the Journal of Neuro-oncology, researchers have found that that patients with benign brain tumours experience greater distress than those with malignant tumours before …
Benefit of PET and PET/CT in ovarian cancer is not proven
Aug 08, 2012
Due to the lack of studies, there is currently no proof that patients with ovarian cancer can benefit from positron emission tomography (PET) alone or in combination with computed tomography (CT). As regards diagnostic accuracy, …
New blood test could offer more tailored treatment of ovarian cancer
Sep 05, 2014
(Medical Xpress)—A new blood test allowing doctors to predict which ovarian cancer patients will respond to particular types of treatment is a step closer following a new study by Manchester scientists.
Recommended for you
New imaging technique identifies receptors for targeted cancer therapy
8 hours ago
Dartmouth researchers have developed a fluorescence imaging technique that can more accurately identify receptors for targeted cancer therapies without a tissue biopsy. They report on their findings in “Quantitative in vivo …
Cutting-edge computer software helps pinpoint aggressiveness of breast cancer tumors
8 hours ago
Researchers at Western University are using cutting-edge genetic mutation-analysis software developed in their lab to interpret mutations in tumour genome that may provide insight into determining which breast …
Conventional therapies are less efficient in cancer patients carrying ‘BRCA’ mutations
13 hours ago
Prostate cancer patients carrying inherited mutations in the BRCA genes respond less well to conventional treatment, including surgery and/or radiotherapy – and they also have a lower survival rate than those …
Chlamydia knocks out the body’s own cancer defence
13 hours ago
Infections due to the sexually transmitted bacterium Chlamydia trachomatis often remain unnoticed. The pathogen is not only a common cause of female infertility; it is also suspected of increasing the ri …
Researchers develop technology to improve lung cancer detection and treatment
13 hours ago
Researchers from Loyola University Chicago Stritch School of Medicine have developed a technology that improves the detection of tumors during radiation therapy for early-stage lung cancer.
Studies on Curaxin CBL0137 in preclinical models of pancreatic cancer
14 hours ago
Cleveland BioLabs, Inc. and Roswell Park Cancer Institute (RPCI) today announced the publication of studies in Oncotarget describing the preclinical efficacy of Curaxin CBL0137 as a single agent and in combination with the …
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
Privacy Policy
Terms of use
Disclaimer
© Medical Xpress 2011-2014, Science X network
Source
The post New test can help doctors choose best treatment for ovarian cancer – Medical Xpress appeared first on Allure Senses.